Fairvalue-Calculator Fairvalue-Calculator
EN DE

DiaMedica Therapeutics Inc (DMAC) Fair Value & Analysis

Healthcare · US · Market cap $315M

Price$6.28
Fair Value$4.69
Upside-25.3%
Quality95/100
Evidence: Low Range $3.51 – $5.86

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

DiaMedica Therapeutics Inc (DMAC) currently trades at $6.28, while our model-based Fair Value estimate is $4.69 — implying the stock looks roughly 25.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is DiaMedica Therapeutics Inc (DMAC) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.69 versus a price of $6.28 — about −25% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DMAC?
Our 21-model fair value for DiaMedica Therapeutics Inc is $4.69 (as of Jun 24, 2026), built from audited fundamentals. The current price is $6.28.
What is the quality score of DMAC?
DiaMedica Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.